The Biosimilars are the authoritatively permitted versions of the innovative biologic drugs, and can be prepared when the original product’s patent deceases. Biosimilars are comparatively inexpensive than their biologic counterparts and hence, consumers have come to choose biosimilars over the biologics in the current years. Not only has this, the biosimilars have an extraordinary capabilities to lower the costs enhancing the patient admittance to life-saving medicines prescription drug costs continue to increase. Moreover, in 2016 the Indian Council for Medical Research predicted approximately 1.4 million new cancer circumstances and by 2020, this number is predicted to increase to 1.7 million. According to the prediction of the International Diabetes Federation, around 82 million people in the SEA economy live with diabetes and the figure is estimated to increase to 151 million by 2045. Whereas, in 2017, the underdeveloped region India alone registered for 72 million cases of diabetes.
The biologics have transformed patient management in numerous disease cases, involving the autoimmune diseases, solid tumors, hematologic malignancies, infectious diseases and hormone deficiencies over the past two decades. According to the expectation of American Cancer Society, nearly 1,688,780 new cancer cases are estimated to be diagnosed and 600,920 are anticipated to die in 2017. According to the report analysis, ‘Global Biosimilars Market 2018-2024’ states that there are several key players which are presently functioning in this sector more actively for leading the fastest market growth and registering the high value of market share across the globe in the coming years while decreasing the restraints, spreading the information related to the application of biosimilars and effectively working with the growth strategies and policies includes Pfizer Inc., Novartis AG, Celltrion Healthcare, Dr. Reddy’s Laboratories Limited, Teva Pharmaceuticals Industries, Biocon Ltd, STADA Arzneimittel AG, Mylan N.V., Amgen Inc., Synthon Pharmaceuticals Samsung Bioepis Co., Ltd and several other niche players.
The Global Biosimilars Market is estimated to witness a CAGR of 57.03% during the forecast period 2018-2024. Nonetheless, the global market of biosimilars is segmented into different sectors which majorly involves applications, regions and products. Whereas, based on the product the market of biosimilars is sectored into recombinant glycosylated protein, recombinant non-glycosylated protein, recombinant peptides, and others. However, the Recombinant glycosylated protein, that involves the monoclonal antibody and erythropoietin, engaged the foremost share in 2017, and is predicted to increase at a high CAGR in the near years owing to the some factors such as augmented patient admittance to treatment owing to its lower cost associated to its corresponding biological drugs, extensive therapeutic applications, and many block buster mAbs going off patent in next few years.
Although, many of the top selling biologic drugs are going off-patent in the next five years, flooring the method for biosimilar players to attain a strong foothold in the market with their advanced product offerings. The key market players are effective attaining the other companies to develop their product portfolio and to toughen their position in the market.
Nevertheless, the significant increase in the incidences of cancer and chronic diseases, cost efficiency of biosimilars over biologics, strategic collaborations, auspicious pipeline of biosimilars with the termination of biologics patents, and an augmented requirement for such drugs in the underdeveloped countries are the primary factors fueling the biosimilar global market.therefore, in the coming years it is predicted that the global market of biosimilars will increase more positively over the recent few years.
For more information on the research report, refer to below link:
Global Biosimilars Market 2018-2024
Related reports
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
